gracecast-102_lung-cancer_immunotherapy: mage-a3, stimuvax, and lucanix, by dr. r. govindan
Published 12 years ago • 536 plays • Length 21:41Download video MP4
Download video MP3
Similar videos
-
8:03
gracecast - immunotherapy for small cell lung cancer with dr. stephen liu
-
13:40
gracecast-104_lung-cancer_immunotherapy for lung cancer: q and a session
-
23:37
gracecast-103_lung-cancer_immunotherapy: yervoy, anti-pd-1, reolysin, talactoferrin by dr. brahmer
-
7:37
gracecastuc-016_lung_a high profile failure for stimuvax: implications for future trials
-
9:36
gracecast-021_lung-cancer_stage iiia management options
-
42:48
immunotherapy for lung cancer
-
4:09
immunotherapy combinations: is this the future for treating lung cancer?
-
5:24
gracecast - lcvl - can immunotherapy help frail patients with advanced nsclc
-
1:36
q&a: does braf in non-smokers respond to immunotherapy? - targeted therapies in lung cancer 2023
-
5:09
gracecastuc-013_lung_what should we do for a "mixed response" to lung cancer treatment?
-
7:41
gracecast-113_lung-cancer_asco 2012 lc highlights: dr. neal on anti-pd-1 immunotherapy for nsclc
-
3:47
gracecast - lcvl what is the role of immunotherapy for unresectable stage 3 nsclc today
-
1:46
immunotherapy for patients with resectable nsclc & driver mutation-targeted therapies in lung cancer
-
6:08
chemo /- immunotherapy for mesothelioma-leading developments & current questions in lung cancer
-
11:36
immunotherapy for lung cancer: currently enrolling clinical trials of combination therapies
-
14:17
gracecast-032_lung-cancer_intro to first line nsclc treatment
-
33:47
gracecast-049_lung-cancer_weiss on egfr therapy for early stage nsclc
-
3:22
acquired resistance in lung cancer treatment - lcvl 2024
-
10:03
kras nsclc: details and diagnosis - targeted therapies in lung cancer 2023